Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
- Autores: Julia H. Hayes, Michael J. Barry
- Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 11, 2014, págs. 1143-1149
- Idioma: inglés
- Enlaces
-
Resumen
Importance Prostate cancer screening with the prostate-specific antigen (0) test remains controversial.
Objective To review evidence from randomized trials and related modeling studies examining the effect of PSA screening vs no screening on prostate cancer–specific mortality and to suggest an approach balancing potential benefits and harms.
Evidence Acquisition MEDLINE, EMBASE, and the Cochrane Register of Controlled Trials were searched from January 1, 2010, to April 3, 2013, for PSA screening trials to update a previous systematic review. Another search was performed in EMBASE and MEDLINE to identify modeling studies extending the results of the 2 large randomized trials identified. The American Heart Association Evidence-Based Scoring System was used to rate level of evidence.
